Roche: joins forces with US drugmaker for COVID treatment
(CercleFinance.com) - Roche said on Thursday that it will team up with US biopharmaceutical firm Atea to develop a potential oral treatment for COVID-19 patients.
The two companies said they are joining forces to develop, manufacture and distribute Atea's investigational antiviral AT-527, which blocks the RNA polymerase enzyme needed for viral replication.
The drug is currently being studied in a phase 2 clinical trial for hospitalised patients with moderate COVID-19, with a phase 3 trial expected to start in early 2021 in outpatients.
Copyright (c) 2020 CercleFinance.com. All rights reserved.